Profile data is unavailable for this security.
About the company
Flerie AB, formerly InDex Pharmaceuticals Holding AB, is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company is an active long-term global biotech and pharmaceutical investor that managing a portfolio of companies in Europe, Israel, and the US. Flerie invests in companies across the entire value chain, providing exposure to opportunities across three segments: Product Development, Commercial Growth, and Limited Partnerships. The Product Development segment consists of early-stage biotech and pharma companies in product development. The Commercial Growth segment consists of companies that are already selling products or services and showcasing proof-of-concept with high growth and some that have already reached profitability. The Limited Partnerships segment provides benefits for the other two segments, including co-investment opportunities, and derisks Flerie’s investment portfolio.
- Revenue in SEK (TTM)100.00k
- Net income in SEK-190.35m
- Incorporated2016
- Employees7.00
- LocationFlerie ABSkeppsbron 16STOCKHOLM 111 30SwedenSWE
- Phone+46 812203850
- Fax+46 850884739
- Websitehttps://www.flerie.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vistin Pharma ASA | 420.49m | 65.61m | 1.22bn | 77.00 | 18.57 | 4.31 | 14.59 | 2.90 | 1.54 | 1.54 | 9.87 | 6.63 | 1.11 | 2.24 | 7.32 | 5,684,247.00 | 17.38 | 1.73 | 22.86 | 2.11 | 61.78 | 58.92 | 15.60 | 2.36 | 0.8687 | -- | 0.1348 | -- | 51.35 | 16.95 | 1,066.84 | -- | -0.1922 | -- |
| Photocure ASA | 493.40m | 12.34m | 1.39bn | 102.00 | 114.30 | 2.89 | 34.53 | 2.81 | 0.4655 | 0.4655 | 18.98 | 18.43 | 0.7233 | 0.8802 | 7.86 | 5,035,059.00 | 1.81 | -3.06 | 2.01 | -3.54 | 94.52 | 93.64 | 2.50 | -5.15 | 5.30 | -- | 0.00 | -- | 27.35 | 22.50 | 101.36 | -- | 49.83 | -- |
| Probi AB | 642.71m | 13.70m | 2.96bn | 162.00 | 216.21 | 2.09 | 26.18 | 4.61 | 1.20 | 1.20 | 56.41 | 124.20 | 0.4045 | 3.25 | 5.91 | 4,016,925.00 | 0.8624 | 4.64 | 0.9144 | 4.98 | 32.88 | 42.04 | 2.13 | 9.83 | 4.69 | -- | 0.0591 | 21.42 | 1.52 | 0.7684 | -58.60 | -26.09 | 31.01 | -- |
| Flerie AB | 100.00k | -190.35m | 3.32bn | 7.00 | -- | 0.0076 | -- | 33,178.22 | -102.92 | -102.92 | 0.0333 | 5,610.13 | 0.00004 | -- | -- | 14,285.71 | -7.86 | -37.64 | -7.99 | -41.14 | -126,944.00 | -450.51 | -190,353.00 | -454.62 | -- | -- | 0.0003 | -- | -- | 277.02 | 5.05 | -- | -- | -- |
| Swedencare AB (publ) | 2.47bn | 76.20m | 6.75bn | 559.00 | 88.53 | 0.8783 | 17.28 | 2.73 | 0.4801 | 0.4801 | 15.58 | 48.39 | 0.2428 | 2.26 | 8.69 | 5,087,037.00 | 0.7483 | 1.38 | 0.7727 | 1.43 | 56.76 | 55.34 | 3.08 | 5.10 | 1.67 | 2.42 | 0.1726 | 45.33 | 27.48 | 88.16 | -37.96 | 20.24 | 30.90 | -- |
| BioGaia AB | 1.37bn | 401.72m | 11.05bn | 220.00 | 28.51 | 7.27 | 25.95 | 8.07 | 3.98 | 3.98 | 13.56 | 15.60 | 0.6749 | -- | -- | 6,520,886.00 | 19.80 | 15.47 | 22.19 | 16.93 | 73.84 | 73.30 | 29.34 | 27.70 | -- | -- | 0.00 | 104.42 | 17.44 | 11.81 | -2.25 | 11.20 | 29.27 | 28.10 |
| Calliditas Therapeutics AB | 1.60bn | -480.36m | 12.37bn | 222.00 | -- | 104.39 | -- | 7.73 | -8.95 | -8.95 | 29.83 | 1.98 | 0.9267 | 3.62 | 8.68 | 8,212,380.00 | -27.80 | -26.46 | -35.11 | -30.27 | 93.46 | -- | -30.00 | -76.59 | 2.59 | -3.07 | 0.9042 | -- | 50.32 | -- | -13.08 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 30 Jun 2024 | 5.46m | 7.00% |
| Atlant Fonder ABas of 30 Aug 2024 | 1.07m | 1.37% |
| SEB Investment Management ABas of 30 Aug 2024 | 106.72k | 0.14% |
| Ponderus Invest ABas of 31 Dec 2023 | 62.00k | 0.08% |
| FCG Fonder ABas of 30 Aug 2024 | 27.42k | 0.04% |
